Navigation Links
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Date:12/9/2007

se among AML patients. These data were presented by Ana I. Romero from the Department of Internal Medicine, University of Goteborg in a presentation entitled, "Histamine Dihydrochloride Maintains Cytoxic Effector T Lymphocyte Function and Viability under Conditions of Oxidative Stress."

In the study, researchers recovered autoreactive T-cells from AML patients and exposed them to exogenous hydrogen peroxide or oxygen radical-producing mononuclear phagocytes. Ceplene, an inhibitor of oxygen radical formation in phagocytes, completely prevented apoptosis in the T-cell subset (n=8, p<0.0001). In the presence of mononuclear phagocytes, Ceplene synergized with IL-2 in promoting cell cycle proliferation. Based on these findings, researchers concluded that the phenotype of T-cells with spontaneous reactivity against AML blasts is highly sensitive to oxidants and that by inhibiting oxygen radical formation, Ceplene efficiently protects these cytotoxic lymphocytes from apoptosis in an environment of oxidative stress. In addition, Ceplene was shown to synergize with IL-2 to activate and expand these T-cells.

About Ceplene

Ceplene is EpiCept's registration-stage compound for the treatment of AML. Ceplene is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene reduces formation of oxygen radicals from phagocytes, inhibiting NADPH oxidase and protecting IL-2-activated NK-cells and T-cells.

Ceplene Clinical Trial History

A pivotal Phase III study for Ceplene in conjunction with IL-2 was conducted in 11 countries and included 320 randomized patients. This study met its primary endpoint of preventing relapse as shown by increased LFS at three years for AML patients in remission. The data demonstrated that patients with AML in complete remission who received 18 months of treatment with Ceplene plus low dose IL-2 experienced a significantly improved
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
9. EpiCept Corporation Announces Pricing of Public Offering
10. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
11. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 The Global and ... study on the current state of the Maleic Anhydride ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:8/27/2014)... Australia (PRWEB) August 27, 2014 ... erratic climatic conditions and fluctuations in global supply and ... the past five years. The industry derives a large ... are subject to global market dynamics, with supply and ... Brazil and India. A strong Australian dollar for the ...
(Date:8/27/2014)... August 27, 2014 UNIWIGS, one of the leading ... pieces, offers big deals and sales on all its products, for ... products can save much on UniWigs hair products in ... they can save $10 with a coupon code LABOR10; while when ... coupon code LABOR50. Besides this deal which coupon code is needed ...
(Date:8/27/2014)... Co-operative Research Centre into Microtechnologies, is coordinating ... innovative solutions based on microtechnologies to tackle ... life sciences, among others. IK4-Ikerlan, Ceit-IK4, IK4-Tekniker, ... with CIC microGUNE on this project, which ... Etortek 2013-2014 programme of the Government of ...
(Date:8/27/2014)... 27, 2014 Catalent, the leading ... solutions for drugs, biologics and consumer health products, ... held Australian biomarker research company, Minomic International Limited, ... for prostate cancer therapy. Under the agreement, Catalent ... study with a view to larger scale production ...
Breaking Medicine News(10 mins):Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:UniWigs Is Offering A Big Sale for Labor Day on All Its Products 2Health News:Microtechnologies for driving forward mobility and human health 2Health News:Catalent and Minomic Collaborate to Bring New Prostate Cancer Treatment to Market 2Health News:Catalent and Minomic Collaborate to Bring New Prostate Cancer Treatment to Market 3
... colleagues from the Institute of Child Health will be studying ... The study will focus on the changes in their brain ... identify and understand the problems in their brain which could ... study is being funded by the Action Medical Research, UK. ...
... grow and currently affects more that 18 million ... need for alternative diabetes therapies with earlier more ... of insulin by the lung may provide an ... alternative insulin delivery systems must meet certain pharmacokinetic ...
... as the Breast Cancer Awareness Month. It is a sad ... and mortality associated with breast cancer//, very few men and ... risk factors and what is to be done in case ... Lauder, founder and president of the Breast Cancer Research Foundation, ...
... Los Angles have taken a major step forward in the ... the development of prostate cancer in animals//. ,The antibody ... and according to Dr. Robert E. Reiter, a professor of ... study's senior author it tells the cancer that it is ...
... known to express endogenous peptide antibiotics called defensins, ... active against bacteria, fungi and viruses//. ... of Nature, describes plectasin-the first defensin to be ... nigrella. Plectasin has primary, secondary and tertiary structures ...
... the deadly HIV/AIDS is accelerating in China with 126,808 ... patients, according to latest health reports//. Experts estimate that ... 80,000 AIDS patients. ,This is considerably higher than the ... over a margin of 19,818. In addition, the patients ...
Cached Medicine News:Health News:New Research To Study Brain Changes In Premature Births 2Health News:HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy 2Health News:Mushroom found to be a source of a new antibiotic: Plectasin 2
(Date:8/27/2014)... Calif. , Aug. 27, 2014  AcelRx Pharmaceuticals, ... company focused on the development and commercialization of innovative ... today announced that senior management will be participating at ... at the Morgan Stanley Global Healthcare Conference.  Details of ... Healthcare One on One Conference Date: Wednesday September 3 ...
(Date:8/26/2014)... 26, 2014 Intelomed is pleased to announce ... the team as the Vice President of Clinical Affairs. ... the medical device industry, Kay,s experience in taking medical ... and development to global expansion, is a valuable addition ... have Kay on our team, and I am confident ...
(Date:8/26/2014)... 26, 2014 Reportlinker.com announces that ... in its catalogue: Japan Esophagoscopes ... http://www.reportlinker.com/p02280977/Japan-Esophagoscopes--Gastroscopes-Market-Outlook-to-2020.html ... 2020 Summary GlobalData,s new report, ... 2020", provides key market data on the ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 3Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 4Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 5
... 24 Schering-Plough Corporation (NYSE: SGP ... selective adenosine2a receptor antagonist, met the primary endpoint ... suffering from moderate to severe Parkinson,s disease experiencing ... The trial results were presented today at the ...
... , Dear President-Elect Obama:, , ... will start with billions of dollars,earmarked for stem cell research. ... is the voice of the Repair Stem Cell research and,treatment ... federal,funding support for our industry and the medical and scientific ...
Cached Medicine Technology:Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: